Patients ( n = @ ) with active RA ( @ swollen and tender joints , C-reactive protein @ mg/L ) on oral DMARDs were randomized ( @:@:@ ) to receive pateclizumab @ mg , adalimumab @ mg , or placebo subcutaneously every @ weeks .